President Donald Trump has stated that the U.S. will “no longer tolerate profit and price gouging” from major pharmaceutical companies, signing an executive order aimed at what his administration describes as a shift toward “the most preferred national drug pricing.”
“The concept is straightforward: Americans should pay the same price for drugs that other developed countries pay,” Trump mentioned at the White House. He indicated that prices for certain prescription medications could decrease by as much as 50-90%.
“From today onward, the U.S. will stop subsidizing healthcare for other nations,” he continued, emphasizing that Americans often pay significantly more for the same drugs. It’s a bit shocking, really.
Despite being just 4% of the global population, the U.S. accounts for over a third of pharmaceutical companies’ profits. So, it’s kind of surprising that they get most of their earnings from such a small percentage of people.
Trump expressed respect for pharmaceutical companies and their achievements but insisted that the current valuation needs a serious rethink. “They’ve made remarkable strides, but it’s time for a change,” he remarked.
The executive order directs trade representatives and the Secretary of Commerce to ensure foreign countries don’t manipulate market prices, potentially inflating costs in the U.S.
Furthermore, the order aims to empower patients by allowing them to purchase drugs directly from manufacturers at these “most favorable country” prices, sidestepping middlemen. If a manufacturer can’t provide acceptable prices, the order would prompt the Secretary of Health and Human Services to establish rules to enforce those prices.
Health and Human Services Secretary Robert F. Kennedy Jr. expressed his surprise at the developments, recalling how his children, who are fans of progressive politics, were deeply moved by the news. “Finally, a president stands up for Americans,” he added.
Trump announced earlier that drug prices could be reduced by 59%. However, the Pharmaceutical Research and Manufacturers of America criticized the order, arguing that it could jeopardize Medicare and access to medicines for patients.
Stephen UBL, the group’s president, claimed that relying on foreign pricing would harm American patients without ensuring any benefit, warning that it might drive companies to seek innovation elsewhere.
“To effectively reduce costs for Americans, we have to confront the underlying factors behind the high prices here,” UBL stated. “In the U.S., entities like pharmacy benefit managers and insurance companies can take a huge chunk of healthcare spending, leaving patients paying more.”
